Xpovio
Karyopharm Therapeutics
Xpovio is an oral medication that treats adults with multiple myeloma that has relapsed or did not respond to previous treatment and adults with certain types of diffuse large B-cell lymphoma.
The pharmaceutical agent is used in combination with dexamethasone in patients who have received at least four prior therapies and whose disease did not respond to at least two proteasome inhibitor medicines, at least two immunomoduatory agents and an anti-CD38 monoclonal antibody medicine.
Xpovio’s most common side effects include tiredness, low red blood cell count, constipation, shortness of breath, increased blood sugar, changes in body salt and in mineral levels in the blood and changes in kidney and liver function blood tests.
Next >>
Filed Under: Drug Discovery, Drug Discovery and Development, Neurological Disease, Oncology, Orphan Drugs
Tell Us What You Think!
You must be logged in to post a comment.